Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | DDX3X | O00571 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20057565 | 0.86 | TP53 (0.60) | MEN1KMT2ADDX3XALDH1A1MAPT | |
| SCHEMBL18814669 | 0.86 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17589369 | 0.86 | KMT2A (0.66) | MEN1KMT2ADDX3XALDH1A1MAPT | |
| SCHEMBL8885278 | 0.85 | ALDH1A1 (0.52) | MEN1KMT2ADDX3XALDH1A1MAPT | |
| SCHEMBL13522506 | 0.85 | MEN1 (0.49) | MEN1KMT2ADDX3XALDH1A1MAPT | |
| SCHEMBL7097165 | 0.82 | ALDH1A1 (0.67) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2632867 | 0.82 | SAE1 (0.68) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20057642 | 0.82 | DDX3X (0.49) | MEN1KMT2ADDX3XALDH1A1MAPT | |
| SCHEMBL11863928 | 0.82 | RAB9A (0.70) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL697192 | 0.82 | GPR35 (0.55) | MEN1KMT2ADDX3XALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180326-B1 | BENZODIAZEPINE DERIVATIVES AS CCK2/GASTRIN RECEPTOR ANTAGONISTS | TRIO MEDICINES LTD (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| WO-2017025727-A1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | TRIO MEDICINES LIMITED (GB) | 2017-02-16 | — | — | WO | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | MEN1 1674/4885KMT2A 4608/4885DDX3X 4769/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | MEN1 1674/4885KMT2A 4608/4885DDX3X 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.